Kaye Edward M. MD 4

What Happened Dr. Edward M. Kaye, a director of Cytokinetics, received equity awards on May 27, 2026. The Form 4 reports acquisition of 2,851 common shares at $0.00 (direct award) and 4,301 derivative shares at $0.00 (derivative award), for a combined total of 7,152 shares. Because these were awards (grants) with $0.00 purchase price, this was not an open‑market purchase or sale but a compensation/award transaction.

Key Details

• Transaction date: 2026-05-27 (reported on Form 4 filed 2026-05-27, so the filing appears timely).
• Price: $0.00 per share for both the direct and derivative awards; total cash exchanged = $0.
• Shares reported acquired: 2,851 direct shares; 4,301 derivative shares (total 7,152).
• Shares owned after transaction: not specified in the excerpt provided. Check the full filing for beneficial ownership after the grant.
• Footnotes/plan details: filing lists the derivative award category; the Form 4 excerpt provided does not show additional footnotes (e.g., 10b5‑1, tax withholding).
• Filing timeliness: the report was filed on the same date as the reported transactions (no late filing flag noted here).

Context Derivative awards typically represent restricted stock units (RSUs) or similar rights to receive shares in the future; they differ from immediate share purchases because they often vest over time and may be subject to forfeiture or other conditions. Awards to directors are commonly part of regular compensation and do not by themselves indicate a personal market buy or sell decision. For full details on vesting, restrictions, or related compensation plan terms, consult the company’s proxy/compensation disclosures and the complete Form 4 filing (accession 0001061983-26-000058).